Our top pick for
Pulmatrix, Inc is a biotechnology business based in the US. Pulmatrix shares (PULM) are listed on the NASDAQ and all prices are listed in US Dollars. Pulmatrix employs 22 staff and has a trailing 12-month revenue of around USD$9.4 million.
|Latest market close||USD$1.1|
|52-week range||USD$0.6103 - USD$2.055|
|50-day moving average||USD$1.1361|
|200-day moving average||USD$1.4047|
|Wall St. target price||USD$10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.467|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-16)||1.1|
|1 month (2020-10-23)||-2.65%|
|3 months (2020-08-24)||-6.78%|
|6 months (2020-05-22)||-41.49%|
|1 year (2019-11-22)||35.80%|
|2 years (2018-11-23)||182.34%|
|3 years (2017-11-24)||-32.52%|
|5 years (2015-11-24)||-77.80%|
|Revenue TTM||USD$9.4 million|
|Gross profit TTM||USD$-4,935,000|
|Return on assets TTM||-23.74%|
|Return on equity TTM||-84.14%|
|Market capitalisation||USD$40.6 million|
TTM: trailing 12 months
There are currently 118,321 Pulmatrix shares held short by investors – that's known as Pulmatrix's "short interest". This figure is 20.9% up from 97,855 last month.
There are a few different ways that this level of interest in shorting Pulmatrix shares can be evaluated.
Pulmatrix's "short interest ratio" (SIR) is the quantity of Pulmatrix shares currently shorted divided by the average quantity of Pulmatrix shares traded daily (recently around 455080.76923077). Pulmatrix's SIR currently stands at 0.26. In other words for every 100,000 Pulmatrix shares traded daily on the market, roughly 260 shares are currently held short.
However Pulmatrix's short interest can also be evaluated against the total number of Pulmatrix shares, or, against the total number of tradable Pulmatrix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pulmatrix's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Pulmatrix shares in existence, roughly 0 shares are currently held short) or 0.0035% of the tradable shares (for every 100,000 tradable Pulmatrix shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pulmatrix.
Find out more about how you can short Pulmatrix stock.
We're not expecting Pulmatrix to pay a dividend over the next 12 months.
Pulmatrix's shares were split on a 1:10 basis on 6 February 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pulmatrix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pulmatrix shares which in turn could have impacted Pulmatrix's share price.
Over the last 12 months, Pulmatrix's shares have ranged in value from as little as $0.6103 up to $2.055. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmatrix's is 1.417. This would suggest that Pulmatrix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.